Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EPS (Basic): 2015-2025

Historic EPS (Basic) for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$0.28.

  • Editas Medicine's EPS (Basic) rose 62.67% to -$0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6.30%. This contributed to the annual value of -$2.88 for FY2024, which is 42.57% down from last year.
  • Per Editas Medicine's latest filing, its EPS (Basic) stood at -$0.28 for Q3 2025, which was up 55.56% from -$0.63 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's EPS (Basic) ranged from a high of -$0.21 in Q4 2023 and a low of -$0.92 during Q1 2025.
  • In the last 3 years, Editas Medicine's EPS (Basic) had a median value of -$0.63 in 2025 and averaged -$0.61.
  • As far as peak fluctuations go, Editas Medicine's EPS (Basic) slumped by 538.46% in 2021, and later surged by 76.14% in 2023.
  • Editas Medicine's EPS (Basic) (Quarterly) stood at -$0.61 in 2021, then crashed by 44.26% to -$0.88 in 2022, then soared by 76.14% to -$0.21 in 2023, then plummeted by 161.90% to -$0.55 in 2024, then spiked by 62.67% to -$0.28 in 2025.
  • Its EPS (Basic) was -$0.28 in Q3 2025, compared to -$0.63 in Q2 2025 and -$0.92 in Q1 2025.